Pfizer profits drop on lower Covid-19 product sales

Pfizer reported a drop in profits on lower sales of Covid-19 related profits Wednesday as it steers investments to other pharmaceutical areas and implements previously announced cost cuts. Much lower sales of Covid-19 vaccine Comirnaty and therapeutic Paxlovid accounted for a 20 percent drop in first-quarter revenues to $14.9 billion compared with the year-ago period.

  News   May 1, 2024   0   43  Add to Reading List
Pfizer profits drop on lower Covid-19 product sales

ARE YOU TIRED OF LOW SALES TODAY?

Connect to more customers on doacWeb

Post your business here..... from NGN1,000

WhatsApp: 09031633831

ARE YOU TIRED OF LOW SALES TODAY?

Connect to more customers on doacWeb

Post your business here..... from NGN1,000

WhatsApp: 09031633831

ARE YOU TIRED OF LOW SALES TODAY?

Connect to more customers on doacWeb

Post your business here..... from NGN1,000

WhatsApp: 09031633831

Pfizer reported a drop in profits on lower sales of Covid-19 related profits Wednesday as it steers investments to other pharmaceutical areas and implements previously announced cost cuts. Much lower sales of Covid-19 vaccine Comirnaty and therapeutic Paxlovid accounted for a 20 percent drop in first-quarter revenues to $14.9 billion compared with the year-ago period.
Read Original   

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow